A detailed history of Creative Planning transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Creative Planning holds 2,896 shares of LGND stock, worth $323,077. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,896
Previous 2,785 3.99%
Holding current value
$323,077
Previous $234,000 23.93%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024

BUY
$82.7 - $110.11 $9,179 - $12,222
111 Added 3.99%
2,896 $290,000
Q2 2024

Aug 15, 2024

BUY
$68.53 - $87.91 $190,856 - $244,829
2,785 New
2,785 $234,000
Q1 2020

May 05, 2020

SELL
$63.37 - $107.88 $614,372 - $1.05 Million
-9,695 Closed
0 $0
Q4 2019

Jan 30, 2020

SELL
$96.94 - $113.59 $1,066 - $1,249
-11 Reduced 0.11%
9,695 $1.01 Million
Q3 2019

Nov 01, 2019

SELL
$86.25 - $120.16 $37,518 - $52,269
-435 Reduced 4.29%
9,706 $966,000
Q2 2019

Jul 26, 2019

SELL
$107.38 - $129.34 $3,650 - $4,397
-34 Reduced 0.33%
10,141 $1.16 Million
Q1 2019

Apr 24, 2019

BUY
$105.93 - $142.47 $67,371 - $90,610
636 Added 6.67%
10,175 $1.28 Million
Q4 2018

Feb 01, 2019

SELL
$128.36 - $272.13 $238,492 - $505,617
-1,858 Reduced 16.3%
9,539 $1.29 Million
Q3 2018

Oct 25, 2018

BUY
$211.18 - $274.49 $159,652 - $207,514
756 Added 7.1%
11,397 $3.13 Million
Q2 2018

Jul 20, 2018

BUY
$150.77 - $207.98 $189,517 - $261,430
1,257 Added 13.4%
10,641 $2.2 Million
Q1 2018

Apr 18, 2018

SELL
$138.63 - $182.62 $13,724 - $18,079
-99 Reduced 1.04%
9,384 $1.55 Million
Q4 2017

Jan 17, 2018

SELL
$128.36 - $147.04 $24,773 - $28,378
-193 Reduced 1.99%
9,483 $1.3 Million
Q3 2017

Oct 17, 2017

BUY
$120.91 - $137.94 $1.17 Million - $1.33 Million
9,676
9,676 $1.32 Million

Others Institutions Holding LGND

About LIGAND PHARMACEUTICALS INC


  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $1.88B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.